Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 21, 2026, titled " Torrent Pharma launches oral and injectable formulations of Semaglutide".
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Torrent Pharmaceuticals has launched Semaglutide in India under brand names Sembolic and Semalix in both oral and injectable forms, targeting type-2 diabetes and obesity (GLP-1 therapy segment). It claims to be the first Indian company to launch a generic oral Semaglutide, with the injectable priced starting at Rs. 3,999 per month. The launch strengthens Torrent's presence in the fast-growing metabolic disorders space, an area seeing strong global demand driven by drugs like Ozempic and Wegovy. Torrent is currently ranked 5th in the Indian pharma market post the JB Pharma acquisition, with annual revenues exceeding Rs. 11,500 crores.
Positive for shareholders — entry into the high-growth GLP-1 segment, especially as a first-mover in the generic oral Semaglutide space, could open a meaningful new revenue stream. However, actual contribution will depend on uptake, competition from other generic launches, and pricing pressure in the segment.